Enhanced therapeutic efficacy of tumor RNA-pulsed dendritic cells after genetic modification with lymphotactin.
Zhang W, He L, Yuan Z, Xie Z, Wang J, Hamada H, Cao X.
Zhang W, et al. Among authors: cao x.
Hum Gene Ther. 1999 May 1;10(7):1151-61. doi: 10.1089/10430349950018148.
Hum Gene Ther. 1999.
PMID: 10340547
In the preestablished 3LL and B16 tumor models, vaccination with DC-based or LacZ-DC-based tumor RNA vaccines (2 X 10(5) cells) could reduce pulmonary metastasis and extend survival of tumor-bearing mice, but was less effective than the Lptn-DC counterpart (with 60-80% mic …
In the preestablished 3LL and B16 tumor models, vaccination with DC-based or LacZ-DC-based tumor RNA vaccines (2 X 10(5) cells) could …